Group items tagged

AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with advanced ovarian cancer. The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without certain mutations. Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added. Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial, said: "DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community." Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary endpoints as well as data for relevant subgroups."

Over the last few years, we've seen the aftermath of Covid-19, with the demand for consumer health products being unprecedented and unpredictable, placing pressure on supply chains and labour market. In turn, the industry has experienced acute shortages across the healthcare sector, placing huge pressure on pharmacists, doctors, nurses, and other healthcare professionals. Europe has an estimated shortage of around 50,000 public-sector doctors[1], which is set to increase in the coming years. While this shortage stems from several complex problems, there is a hidden force that could play a key part in helping to alleviate this burden. That force is the potential of self-care. Encouragingly, last month the UK government recognised the unique role that self-care can play through the introduction of its Delivery plan for recovering access to primary care. Through this, it has pledged to empower patients to manage their own health through several commitments, including improving accessibility to online tools and reclassifying medicines to make formerly prescribed options available over the counter.

The Department of Health and Social Care (DHSC) has published the full text of the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG). The 2024 VPAG agreement text sets out the detailed terms of the agreement reached between DHSC, NHS England and the Association of the British Pharmaceutical Industry (ABPI) to support patient access to medicines, the financial sustainability of the NHS and the UK life sciences sector. The new voluntary scheme will come into force on 1 January 2024, following expiry of the 2019 Voluntary Scheme and shall remain in force for a period of five years, until 31 December 2028. Manufacturers or suppliers of branded medicines to the NHS have been given time till 15 January 2024 to decide whether to join the new 2024 Voluntary Scheme, or default to the updated Statutory Scheme.

What initially began as two close friends taking a leisurely walk to escape their everyday routine has evolved into a meaningful endeavour to support the fight against cancer. Jamie Sparrow, Senior Vice President - Commercial, EMENA at Accord Healthcare, and Jamie Durbidge, Owner & Managing Director of Perennial Pharma, will be undertaking a 5-day walking challenge to support The Luke Hart Foundation in raising funds for Cancer Research UK. The two Jamies have been friends for more than 15 years and worked together at Mylan, now Viatris, where Jamie S served as Managing Director, while Jamie D held the position of Sales Director for some years. During the COVID pandemic when everybody was stuck at home, the two friends, both early risers, used to spend hours in the mornings walking and talking over the phone, about anything and everything - work, life, family, the Pharmaceutical Industry, politics, sport, and about challenges that people were having during the lockdown. After continuing this routine for several months, they eventually planned to transform their daily ritual into a "walking and talking" trip to reconnect, catch up on things, and enjoy some time together and with friends who wanted to join them.

The World Health Organization (WHO) reiterated its concerns about tobacco companies' continued targeting of young people through various channels such as social media, sports, and music festivals, as well as the introduction of flavored products. In a joint report with industry watchdog STOP released on Thursday, the WHO accused these companies of attempting to ensnare a new generation in nicotine addiction. While facing stricter regulations on traditional cigarettes, major tobacco firms and newcomers have turned to alternatives like vapes, arguing they are intended for adult smokers. However, the WHO and STOP highlighted in their report that these products often appeal to youth, with their attractive designs and fruity flavors making them more appealing to children than to adults in many countries.

Louth and Horncastle's MP Victoria Atkins has taken the new role of Health Secretary today (13 November) amid the PM's cabinet reshuffle. Steve Barclay, the former Secretary of State for Health and Social Care was moved to become Environment Secretary after being assigned the role of Health Secretary. The following decision was made consequent to Steve Barclay being reassigned from the role. The news comes at a time when the NHS faces enduring challenges and industrial action, making this change particularly significant. MP Atkins is married to Paul Kenward, managing director of British Sugar, which also grows medicinal cannabis.

Pharma giant, Pfizer has announced plans to cut 500 jobs at its Sandwich site in Kent, England as part of its ongoing $3.5 billion cost-cutting drive. The company is also planning to shut its Pharmaceutical Sciences Small Molecule (PSSM) capabilities at the site, a spokesperson of the company told FiercePharma. However, the Sandwich site will remain open and other functions will continue with "a different size," the spokesperson added. Currently, around 940 people are employed at the site, which is the location where Pfizer scientists first discovered Viagra. "We are proud of our heritage of breakthrough science in the UK and we will retain a scientific presence in the U.K. including at our Discovery Park location in Sandwich," Pfizer's spokesperson confirmed in an email to FiercePharma.